This “TIGIT inhibitors - Competitive landscape, 2022” report provides comprehensive insights about 18+ companies and 20+ drugs in TIGIT inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Future of Competitive Landscape of TIGIT inhibitors is estimated to be very strong. Key emerging drugs include BeiGene, Ociperlimab and many other.
This product will be delivered within 1-3 business days.
Geography Covered
- Global coverage
TIGIT inhibitors: Understanding
TIGIT inhibitors: Overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistally, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.Report Highlights
- In December 2021, Bio-Thera Solutions a commercial-stage pharmaceutical company announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.
- In June 2021, GlaxoSmithKline and iTeos Therapeutics announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial.
Company Profiles & their Late-stage Drug Profiles
1. Company Overview: BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, company is committed to expediting the development of our diverse pipeline of novel therapeutics through collaborations or our own internal capabilities, with the aspirational goal of radically improving access to medicines for two billion more people by 2030.Product Description: Ociperlimab
Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, resulting in activation of T cell mediated antitumor immune responses.2. Company Overview: Bio-Thera Solutions
Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases.Product Description: BAT6005
BAT6005 is a monoclonal antibody targeting TIGIT in cancer patient volunteers. BAT6005 was discovered using Bio-Thera's proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, and it has normal IgG1 ADCC function.Future of Competitive Landscape of TIGIT inhibitors is estimated to be very strong. Key emerging drugs include BeiGene, Ociperlimab and many other.
TIGIT inhibitors Analytical Perspective
In-depth TIGIT inhibitors analysis: Assessment of Products
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.TIGIT inhibitors clinical assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type.TIGIT inhibitors Report Assessment
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing TIGIT inhibitors drugs?
- How many TIGIT inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIGIT inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TIGIT inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TIGIT inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Merck Sharp & Dohme
- Bristol-Myers Squibb
- BeiGene
- Arcus Biosciences
- iTeos Therapeutics
- Mereo BioPharma
- Phio Pharmaceuticals
- Bio-Thera Solutions
- Compugen
Key Products
- Vibostolimab
- BMS 986442
- Ociperlimab
- Domvanalimab
- EOS 448
- Etigilimab
- PH 804-TME
- PH 804-ACT
- BAT6005
- Vibostolimab
- M 6223
- COM 902
- BMS 986442
This product will be delivered within 1-3 business days.
Table of Contents
IntroductionExecutive Summary
TIGIT inhibitors: Overview
- Classifications of TIGIT inhibitors
- Applications of TIGIT inhibitors
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
TIGIT inhibitors - Analytical Perspective
BeiGene
- Company overview
- Product in development
Ociperlimab: BeiGene
- Product Description
- Research and Development
- Product Development Activities
iTeos Therapeutics
- Company overview
- Product in development
EOS-488: iTeos Therapeutics
- Product Description
- Research and Development
Bio-Thera Solutions
- Company overview
- Product in development
BAT6005: Bio-Thera Solutions
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
TIGIT inhibitors Key Companies
TIGIT inhibitors Key Products
TIGIT inhibitors - Unmet Needs
TIGIT inhibitors - Market Drivers and Barriers
TIGIT inhibitors - Future Perspectives and Conclusion
TIGIT inhibitors Analyst Views
TIGIT inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for TIGIT inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for TIGIT inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck Sharp & Dohme
- Bristol-Myers Squibb
- BeiGene
- Arcus Biosciences
- iTeos Therapeutics
- Mereo BioPharma
- Phio Pharmaceuticals
- Bio-Thera Solutions
- Compugen
